Compare SIBN & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SIBN | VALN |
|---|---|---|
| Founded | 2008 | 2012 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 778.8M | 653.3M |
| IPO Year | 2018 | 2021 |
| Metric | SIBN | VALN |
|---|---|---|
| Price | $18.54 | $6.67 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 2 |
| Target Price | ★ $23.88 | $15.50 |
| AVG Volume (30 Days) | ★ 505.2K | 27.6K |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 41.33 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $67,301,000.00 | N/A |
| Revenue This Year | $16.95 | N/A |
| Revenue Next Year | $14.93 | $93.87 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 21.53 | N/A |
| 52 Week Low | $11.48 | $4.75 |
| 52 Week High | $21.89 | $12.23 |
| Indicator | SIBN | VALN |
|---|---|---|
| Relative Strength Index (RSI) | 51.17 | 55.11 |
| Support Level | $18.34 | $6.29 |
| Resistance Level | $19.35 | $6.69 |
| Average True Range (ATR) | 0.64 | 0.20 |
| MACD | -0.07 | -0.07 |
| Stochastic Oscillator | 42.74 | 26.92 |
SI-BONE Inc is a medical device company that develops and commercializes a proprietary minimally invasive surgical implant system in the United States and internationally. Its products include a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products such as iFuse-3D, iFuse-TORQ, and iFuse Bedrock Granite, which have applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma.
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.